Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iressa + Docetaxel + Cisplatin in Recurrent/Metastatic Head and Neck Cancer
NCT00242762Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2003
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by AstraZeneca. Primary endpoint: Objective Response Rate. Started Jul 2003; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00242762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00242762.